

We Aspire to Cure Cancer

WHO WE ARE

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a strong connection from research to development to commercialization. This helps us rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.

TAKEDA ONCOLOGY IS OPTIMIZED TO BRING TRANSFORMATIVE MEDICINES TO MARKET

- We put patients first and strive to build lasting relationships with people who have cancer and their caregivers
- Leadership team with proven experience to drive future growth
- Built for agility with the resources of a large company that has more than two centuries of heritage

A GLOBAL FOOTPRINT

70⁺ Countries with Takeda Oncology presence

10 Global hubs in the United States, Japan, Germany, Spain & Portugal (Iberia), France, Italy, the United Kingdom/Ireland and Canada

10 Approved therapies, with multiple opportunities for potential approved uses

ADDRESSING MULTIPLE DISEASE AREAS WITH OUR ONCOLOGY THERAPIES ACROSS THE GLOBE

Solid Tumor



- ALK+ metastatic NSCLC
- ALK+ advanced NSCLC

Hematology



- Multiple myeloma
- Lymphomas
- Leukemias

WE COMPLEMENT OUR DEEP IN-HOUSE EXPERTISE WITH SYMBIOTIC PARTNERSHIPS TO UNLOCK THE MOST PROMISING SCIENCE - WHEREVER IT EMERGES.

Partnerships are key drivers of our R&D approach. Our collaborations with academic, biotechnology and pharmaceutical partners have resulted in an early development program comprising diverse cutting-edge platforms.

For more information, visit [TakedaOncology.com](https://www.takedaoncology.com)

All trademarks are the property of their respective owners.

©2021 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

All rights reserved.

USO-XMP-0113, 03/21



ONCOLOGY